

Rev 1: September 2018  
FSN Ref: FSN-2020-0008

FSCA Ref: FSN-2020-0008

Date: 29 October 2020

**Urgent Field Safety Notice**  
**Thermo Scientific™ Oxoid™ Brilliance™ Staph24 Agar**

For Attention of\*: Lab Managers

Contact details of local representative (name, e-mail, telephone, address etc.)*
--

Email: mbd.vigilance@thermofisher.com
---------------------------------------


Telephone: +44(0) 1256 841144
-------------------------------

Fax: +44(0) 1256 479525
-------------------------

**Urgent Field Safety Notice (FSN)**  
**Thermo Scientific™ Oxoid™ Brilliance™ Staph24 Agar**

<b>1. Information on Affected Devices*</b>	
1.	1. Device Type(s)* Prepared Microbial Culture Media
1.	2. Commercial name(s) Brilliance™ Staph24 Agar
1.	3. Unique Device Identifier(s) (UDI-DI) n/a
1.	4. Primary clinical purpose of device(s)* For isolation and enumerate coagulase-positive staphylococci in food or clinical samples.
1.	5. Device Model/Catalogue/part number(s)* PO1186A
1.	6. Software version n/a
1.	7. Affected serial or lot number range Lot 4276065
1.	8. Associated devices None


<b>2 Reason for Field Safety Corrective Action (FSCA)*</b>	
2.	1. Description of the product problem* A technical investigation has concluded that this batch may contain low level bacterial contamination, which is sub-surface but has a similar morphological appearance to the target organism
2.	2. Hazard giving rise to the FSCA* Potential to generate false positives if contamination not noted prior to use.
2.	3. Probability of problem arising Low
2.	4. Predicted risk to patient/users There should be no significant immediate or long-term health consequences from using this product. It appears that the contamination while appearance is similar to staphylococci on this chromogenic agar, is very low level, but may not be visible until after incubation.
2.	5. Further information to help characterise the problem Photograph of contamination



2.	6. Background on Issue
	Customer complaints received for low level bacterial contamination. Confirmed in reference material
2.	7. Other information relevant to FSCA
	Lot 4276065 expiry date 27-Oct-2020

3. Type of Action to mitigate the risk*	
3.	<p>1. Action To Be Taken by the User*</p> <p> <input checked="" type="checkbox"/> Identify Device                        <input checked="" type="checkbox"/> Quarantine Device                        <input type="checkbox"/> Return Device                        <input checked="" type="checkbox"/> Destroy Device                 </p> <p> <input type="checkbox"/> On-site device modification/inspection                 </p> <p> <input type="checkbox"/> Follow patient management recommendations                 </p> <p> <input type="checkbox"/> Take note of amendment/reinforcement of Instructions For Use (IFU)                 </p> <p> <input type="checkbox"/> Other                      <input type="checkbox"/> None                 </p>
3.	<p>2. By when should the action be completed?</p> <p style="text-align: right;">Immediately</p>
3.	<p>3. Particular considerations for:                      IVD</p> <p>Is follow-up of patients or review of patients' previous results recommended?</p> <p>No</p> <p>We request that the requirement for review of reported test results should be determined by the appropriate technical expert</p>
3.	<p>4. Is customer Reply Required? *</p> <p style="text-align: right;">Yes</p>

	(If yes, form attached specifying deadline for return)	
3.	5. Action Being Taken by the Manufacturer	
	<input type="checkbox"/> Product Removal <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Software upgrade <input type="checkbox"/> IFU or labelling change <input type="checkbox"/> Other <input type="checkbox"/> None	
3	6. By when should the action be completed?	Immediate
3.	7. Is the FSN required to be communicated to the patient /lay user?	No
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet?	
	No      Choose an item.	

	<b>4. General Information*</b>	
4.	1. FSN Type*	New
4.	2. For updated FSN, reference number and date of previous FSN	n/a
4.	3. For Updated FSN, key new information as follows:	
	n/a	
4.	4. Further advice or information already expected in follow-up FSN? *	Not planned yet
4	5. If follow-up FSN expected, what is the further advice expected to relate to:	
	n/a	
4	6. Anticipated timescale for follow-up FSN	n/a
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)	
	a. Company Name	Thermo Fisher Scientific
	b. Address	Wade Road, Basingstoke, Hampshire RG24 8PW
	c. Website address	www.thermofisher.com/microbiology
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *	
4.	9. List of attachments/appendices:	Customer Response Form
4.	10. Name	Jim Filer, Vice President, Quality and Regulatory, MBD
	Signature	

---

<b>Transmission of this Field Safety Notice</b>	
	<p>This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)</p> <p>Please transfer this notice to other organisations on which this action has an impact. (As appropriate)</p> <p>Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.</p> <p>Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.*</p>

### Customer Reply Form

1. Field Safety Notice (FSN) information			
FSN Reference number*		FSN-2020-0008	
FSN Date*		29 October 2020	
Product/ Device name*		Thermo Scientific™ Oxoid™ Brilliance™ Staph24 Agar	
Product Code(s)		PO1186A	
Batch/Serial Number (s)		4276065	
2. Customer Details			
Account Number			
Organisation Name*			
Organisation Address*			
Department/Unit			
Shipping address if different to above			
Contact Name*			
Title or Function			
Telephone number*			
Email*			
3. Customer action undertaken on behalf of Healthcare Organisation			
<input type="checkbox"/>	I confirm receipt of the Field Safety Notice and that I read and understood its content.		
<input type="checkbox"/>	I performed all actions requested by the FSN.		
<input type="checkbox"/>	The information and required actions have been brought to the attention of all relevant users and executed.		
<input type="checkbox"/>	I have returned affected devices - enter number of devices returned and date complete or <b>N/A</b>	Qty:	Lot/Serial Number: N/A
		Date Returned (DD/MM/YY) : N/A	
		Comments: N/A	
<input type="checkbox"/>	I have destroyed affected devices – enter number destroyed and date complete.	Qty:	Lot/Serial Number:
		Date Returned (DD/MM/YY)	
		Qty	Credit <input type="checkbox"/>
		Comments:	
<input type="checkbox"/>	No affected devices are available for return/ destruction		
<input type="checkbox"/>	Other Action (Define):		
<input type="checkbox"/>	I do not have any affected devices.		
<input type="checkbox"/>	I have a query please contact me (e.g. need for replacement of the product).		
Print Name*			
Signature*			
Date*			
4. Return acknowledgement to sender			
Email		<a href="mailto:MBD.vigilance@thermofisher.com">MBD.vigilance@thermofisher.com</a>	
Telephone Number & Fax		Tel : +44(0) 1256 841144 Fax :+44(0) 1256 479525	
Postal Address			
Deadline for returning the reply form*		<b>26 November 2020</b>	

Mandatory fields are marked with \*

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.